Background:
HU-308 is a selective agonist of CB2-receptor with a Ki value of 20 nM. The Ki value for CB1-receptor is >10 μM.
Cannabinoid 2 receptor (CB2-receptor) belongs to the seven transmembranes G protein-coupled receptor superfamily. It is mainly distributed in peripheral tissue associated with immune functions.
In HLSECs, HU-308 markedly reduced the expression of both ICAM-1 and VCAM-1, which was induced by TNFα. HU-308 attenuated TNF- treatment induced RhoA activation (4.0-fold vs. control) and NF-B Activation. HU-308 inhibited TNFα-induced monocyte adhesion in aortas ex vivo [1].
HU-308 increased both primary neurosphere generation and neural progenitor self-renewal. HU-308 increased the number of BrdU incorporating cells in a CB2-dependent manner. HU-308 stimulated ERK and Akt [2].
Pretreatment of mice with HU-308 decreases the I/R-induced tissue damage, inflammatory cell infiltration, tissue and serum TNF-α, MIP-1, and MIP-2 levels, tissue lipid peroxidation and apoptosis [3].
参考文献:
1.Rajesh M, Mukhopadhyay P, Bátkai S, et al. CB2-receptor stimulation attenuates TNF-alpha-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion. Am J Physiol Heart Circ Physiol. 2007 Oct;293(4):H2210-8.
2.Palazuelos J, Aguado T, Egia A, et al. Non-psychoactive CB2 cannabinoid agonists stimulate neural progenitor proliferation. FASEB J. 2006 Nov;20(13):2405-7.
3.Rajesh M, Pan H, Mukhopadhyay P, et al. Cannabinoid-2 receptor agonist HU-308 protects against hepatic ischemia/reperfusion injury by attenuating oxidative stress, inflammatory response, and apoptosis. J Leukoc Biol. 2007 Dec;82(6):1382-9.
动态评分
0.0